A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors

View at publisher Summarise with VIRAT

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Innervation of tumors can promote tumor growth by impairing antitumor immunity (From Sanu N via Wikimedia Commons).Two studies identify distinct neuro–cellular circuits that impair antitumor immunity. Targeting the circuits enhances antitumor immune responses. In a preclinical model, Wei and colleagues find that vagal sensory nerves transmit signals from lung adenocarcinomas to brainstem nuclei, which increase sympathetic efferent activity and noradrenaline levels in the tumor microenvironment. Noradrenaline, acting via β2 adrenergic receptors, promotes alveolar macrophages to acquire an immunosuppressive phenotype. Zhang and colleagues show that sensory neurons are the main neuron type in triple-negative breast cancer clinical samples. In mouse models, tumor-derived nerve growth factor causes sensory neurons to release calcitonin gene-related peptide, which activates myofibroblastic cancer–associated fibroblasts that increase collagen deposition, leading to immune exclusion.Wei HK, …, Jin C.Nature 2026 Feb 04;650,1007–1016.Zhang SW, …, Jiang YZ. Cell 2026 Feb 5;189,1039–1055.e20.Homotypic SLAMF6 cis interactions impair antitumor immunity (from Emw via Wikimedia Commons).The role of signaling lymphocytic activation molecule 6 (SLAMF6) on T cells is equivocal. Using Slamf6−/− mice on a pure C57BL/6 background, Li and colleagues show that SLAMF6 inhibits CD4+ and CD8+ T-cell activation in vitro and CD8+ T cell–mediated antitumor immunity in vivo. Mechanistically, homotypic SLAMF6 cis interactions inhibit proximal T cell–receptor signaling through SHP-1. Monoclonal antibody–mediated blockade of human SLAMF6–SLAMF6 cis interactions enhances T-cell activation in vitro and reduces tumor growth in multiple preclinical models in which mouse Slamf6−/− T cells are engineered to express human SLAMF6. The data highlight the potential for immunotherapeutic targeting of SLAMF6.Li B, …, Veillette A. Nature 2026 Feb 11;DOI:10.1038/s41586-026-10106-5.Cancer cell colonization of lymph nodes induces cellular reorganization (from Ed Uthman via Wikimedia Commons).To increase understanding of how cancer cell colonization of lymph nodes (LN) causes tumor-specific immune tolerance and thereby promotes distant metastasis, Haist and colleagues performed multi-modal spatial analysis of paired primary tumor and LN samples from patients with head and neck cancer and an in vivo model of melanoma LN metastasis. LN colonization is shown to induce cellular reorganization of the tumor-colonized LN, primary tumor, and nearby tumor-free LNs. There is enrichment of immunosuppressive myeloid cells and cancer-associated fibroblasts that form niches that spatially intersect with perifollicular T-cell zones and LN follicles. Such spatial organization is linked to enhanced T-cell dysfunction, highlighting how LN colonization modulates immune responses.Haist M, …, Nolan GP. Cancer Cell 2026 Jan 29;44,604–623.e9.Humoral immunity impacts immunotherapy efficacy (from NIAID via Wikimedia Commons).How do B cells impact antitumor immunity and immunotherapy outcomes? Using single-cell, bulk, and B-cell receptor (BCR) sequencing, as well as spatial transcriptomics and survival analyses, Gonzalez-Kozlova and colleagues investigated humoral immunity in hepatocellular carcinoma patients treated with anti–PD-1. In responders, defined as having more than 50% tumor necrosis, there is tumor-enriched IgG1 class switching, clonal expansion, and increased plasma cell differentiation and trafficking between the tumor and draining lymph nodes. The IgG1 antibodies are specific for cancer/testis antigens such as MAGE-A and NY-ESO-1. Nonresponders, however, have dysfunctional memory B cells, suggesting humoral immunity impacts antitumor responses and survival following immunotherapy.Gonzalez-Kozlova E, …, Gnjatic S. Nat Med 2026 Jan 27;DOI:10.1038/s41591-025-04177-6.Engineered cytokines for Trikine immunotherapeutics (from scientificanimations.com via Wikimedia Commons).Rodriguez and colleagues report the generation of Trikines, which are engineered cytokines that induce formation of three-chain cytokine receptor complexes that initiate STAT signaling programs that naturally occurring cytokines cannot, with the goal of enhancing antitumor immunity. Each of the Trikines generated drives a specific trimeric combination of the IL2, IL10, and IL21 receptor subunits to activate distinct phospho-STAT5 and phospho-STAT3 signatures. In preclinical mouse models of melanoma, small cell lung cancer, and pancreatic cancer, use of an IL2-based Trikine and an IL10-based Trikine increases T-cell stemness and tumor control without toxicities, highlighting the therapeutic potential of these engineered cytokines.Rodriguez GE, …, Garcia KC. Science 2026 Feb 19;10.1126/science.adx9954.Fecal microbiota transplantation improves immunotherapies (from NIAID via Wikimedia Commons).The microbiome can impact immunotherapy efficacy. Three studies report promising results from clinical trials evaluating fecal microbiota transplantation (FMT) alongside cancer immunotherapy. The phase I PERFORM trial, which investigated healthy donor FMT combined with various immune checkpoint inhibitor (ICI) regimens for metastatic renal cell carcinoma (mRCC), met its primary endpoint of safety. The phase II FMT-LUMINate trial also met its primary endpoint, with an objective response rate of 80% among non–small cell lung cancer patients who received healthy donor FMT and anti–PD-1. Although the phase II TACITO trial did not meet its primary endpoint, patients with mRCC who received pembrolizumab and axitinib with FMT from complete ICI responders had significantly longer median progression-free survival than those receiving placebo FMT, suggesting potential efficacy.Fernandes R, …, Maleki Vareki S. Nat Med 2026 Jan 28;DOI:10.1038/s41591-025-04183-8.Duttagupta S, …, Elkreif A. Nat Med 2026 Jan 28;DOI:10.1038/s41591-025-04186-5.Porcari S, …, Ianiro G. Nat Med 2026 Jan 28;DOI:10.1038/s41591-025-04189-2.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Cancer Stress Anesthesia and Immune Response T-cell and B-cell Immunology

Publication details

Journal / source
Cancer Immunology Research
Volume
14
Issue
4
Pages
527–527
Publication date
2 April 2026
Language
EN